Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

NCT04061239 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

MDS
AML

Interventions

DRUG: CPX-351
DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: Azacitidine

Sponsor

GWT-TUD GmbH